Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations

BACKGROUND: We aimed to determine the clinical. outcomes of various immune checkpoint inhibitor (ICI) combinations for the treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. The results predicted the treatment efficacy of these combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Jinfei, Hao, Yue, Wei, Jingwen, Xiang, Jing, Xu, Chunwei, Shen, Qiuping, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161453/
https://www.ncbi.nlm.nih.gov/pubmed/37147602
http://dx.doi.org/10.1186/s12890-023-02466-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161453/
https://www.ncbi.nlm.nih.gov/pubmed/37147602
http://dx.doi.org/10.1186/s12890-023-02466-9

Ejemplares similares